Physiology-based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P-glycoprotein induction and concurrent inhibition

Br J Clin Pharmacol. 2023 Jul;89(7):2329-2331. doi: 10.1111/bcp.15740. Epub 2023 Apr 19.

Authors

Dirk Theile¹, Julie Nilles^{1

2}, Andreas D Meid¹

Affiliations

¹ Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
² Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

PMID: 37077127
DOI: 10.1111/bcp.15740

No abstract available

Keywords: P-glycoprotein (P-gp); dolutegravir; drug-drug interactions; physiology-based pharmacokinetics; population pharmacokinetics; rifabutin.

Publication types

Letter
Comment

MeSH terms

ATP Binding Cassette Transporter, Subfamily B, Member 1* / metabolism
Humans
Kinetics
Pyridones
Rifabutin* / pharmacokinetics

Substances

Rifabutin
dolutegravir
ATP Binding Cassette Transporter, Subfamily B, Member 1
Pyridones